IC
PALI icon

Ikarian Capital’s Palisade Bio PALI Stock Holding History

Ikarian Capital’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.57M Buy
750,000
+475,022
+173% +$935K 0.17% 96
2026
Q1 		$481K Hold
274,978
– – 0.04% 128
2025
Q4 		$646K Buy
+274,978
New +$529K 0.05% 133

Other funds holding PALI

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Ikarian Capital's PALI Position: Q2 2026 in Review

Ikarian Capital increased its Palisade Bio (PALI) stake by 173% in Q2 2026, buying an estimated $935K and bringing the position to 750,000 shares worth $1.57M. The position accounts for 0.17% of the portfolio, ranked #96.

Ikarian Capital first reported a position in PALI in Q4 2025 and has held it in 3 quarters since. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • Ikarian Capital held 750,000 shares of Palisade Bio worth $1.57M as of Q2 2026.
  • Ikarian Capital bought 475,022 Palisade Bio shares in Q2 2026, an estimated $935K.
  • Palisade Bio made up 0.17% of Ikarian Capital's portfolio in Q2 2026, its #96 holding.
  • Ikarian Capital first reported a position in Palisade Bio in Q4 2025 and has held it in 3 quarters since.
  • 124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.